PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
8.95%
Revenue growth 1.25-1.5x 3088.T's 6.84%. Bruce Berkowitz would check if differentiation or pricing power justifies outperformance.
3.35%
Gross profit growth under 50% of 3088.T's 8.41%. Michael Burry would be concerned about a severe competitive disadvantage.
-4.69%
Negative EBIT growth while 3088.T is at 0.67%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-15.56%
Negative operating income growth while 3088.T is at 11.09%. Joel Greenblatt would press for urgent turnaround measures.
4.01%
Positive net income growth while 3088.T is negative. John Neff might see a big relative performance advantage.
4.00%
Positive EPS growth while 3088.T is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
4.00%
Positive diluted EPS growth while 3088.T is negative. John Neff might view this as a strong relative advantage in controlling dilution.
-0.00%
Share reduction while 3088.T is at 0.00%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-0.00%
Reduced diluted shares while 3088.T is at 0.00%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
2.70%
10Y revenue/share CAGR under 50% of 3088.T's 42.97%. Michael Burry would suspect a lasting competitive disadvantage.
2.70%
5Y revenue/share CAGR under 50% of 3088.T's 42.97%. Michael Burry would suspect a significant competitive gap or product weakness.
-21.41%
Negative 3Y CAGR while 3088.T stands at 25.35%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
-100.00%
Negative 10Y OCF/share CAGR while 3088.T stands at 100.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-100.00%
Negative 5Y OCF/share CAGR while 3088.T is at 100.00%. Joel Greenblatt would question the firm’s operational model or cost structure.
-100.00%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
7.58%
Below 50% of 3088.T's 81.05%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
7.58%
Below 50% of 3088.T's 81.05%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
-26.90%
Negative 3Y CAGR while 3088.T is 7.51%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
36.05%
10Y equity/share CAGR at 50-75% of 3088.T's 56.83%. Martin Whitman would note a lag in capital accumulation vs. the competitor.
36.05%
5Y equity/share CAGR at 50-75% of 3088.T's 56.83%. Martin Whitman would question a shortfall in capital accumulation vs. the competitor.
-8.39%
Negative 3Y equity/share growth while 3088.T is at 38.30%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-14.29%
Negative near-term dividend growth while 3088.T invests at 14797.75%. Joel Greenblatt sees a weaker short-term distribution policy unless justified by strategic spending.
25112.50%
AR growth well above 3088.T's 13.22%. Michael Burry fears inflated revenue or higher default risk in the near future.
1.54%
We show growth while 3088.T is shrinking stock. John Neff wonders if the competitor is more disciplined or has weaker demand expectations.
10.94%
Asset growth above 1.5x 3088.T's 1.29%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
4.72%
BV/share growth above 1.5x 3088.T's 2.62%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
116.68%
Debt growth far above 3088.T's 46.21%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
-31.48%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.